GSK.L Live signals | Maximize Profits with Getagraph.com

Live Chart Being Loaded With Signals

Commentary (19 Apr 2024 @ 03:33):

Stats
Today's Volume	106 914
Average Volume	9.10M
Market Cap	64.04B
EPS	£0 ( 2024-01-31 )
Next earnings date	( £0.290 ) 2024-04-30
Last Dividend	£14.00 ( 2023-08-17 )
Next Dividend	£0 ( N/A )
P/E	13.15
ATR14	£1.267 (0.08%)

Volume Correlation

Long: 0.28 (neutral)

Short: -0.92 (very strong negative)

Signal:(38.462) Neutral

GlaxoSmithKline PLC Correlation

10 Most Positive Correlations

10 Most Negative Correlations

Did You Know?

Correlation is a statistical measure that describes the relationship between two variables. It ranges from -1 to 1, where -1 indicates a perfect negative correlation (as one variable increases, the other decreases), 1 indicates a perfect positive correlation (as one variable increases, the other increases), and 0 indicates no correlation (there is no relationship between the variables).

Correlation can be used to analyze the relationship between any two variables, not just stocks. It's commonly used in fields such as finance, economics, psychology, and more.

GlaxoSmithKline PLC Correlation - Currency/Commodity

0.34
( neutral )

0.28
( neutral )

0.00
( neutral )

0.37
( neutral )

-0.38
( neutral )

0.47
( neutral )

GlaxoSmithKline PLC Financials

Annual	2023
Revenue:	£30.33B
Gross Profit:	£21.25B (70.07 %)
EPS:	£1.220

Q4	2023
Revenue:	£8.05B
Gross Profit:	£5.71B (70.96 %)
EPS:	£0.0863

Q3	2023
Revenue:	£8.15B
Gross Profit:	£5.88B (72.11 %)
EPS:	£0.360

Q2	2023
Revenue:	£7.18B
Gross Profit:	£5.25B (73.08 %)
EPS:	£0.400

Financial Reports:

No articles found.

GlaxoSmithKline PLC Dividends

(Q3/22)	(Q4/22)	(Q1/23)	(Q2/23)	(Q3/23)	(Q4/23)	(Q1/24)	(Q2/24)	(Q3/24)	(Q4/24)
£16.25 (N/A)	£13.75 (N/A)	£13.75 (N/A)	£14.00 (N/A)	£14.00 (N/A)	£0 (N/A)	£0 (N/A)	£0 (N/A)	£0 (N/A)	£0 (N/A)

GlaxoSmithKline PLC Dividend Information - Dividend King

Dividend Sustainability Score: 9.66 - good (96.56%) | Divividend Growth Potential Score: 7.40 - Increase likely (48.04%)

Very Unsafe

High risk of being cut

Unsafe

Heightened risk of being cut

Borderline

Moderate risk of being cut

Safe

Unlikely to be cut

Very Safe

Very unlikely to be cut

Information

First Dividend	£8.75	1993-03-01
Last Dividend	£14.00	2023-08-17
Next Dividend	£0	N/A
Payout Date	0000-00-00
Next Payout Date	N/A
# dividends	107	--
Total Paid Out	£2 098.00	--
Avg. Dividend % Per Year	3.06%	--
Score	6.28	--
Div. Sustainability Score	9.66
Div.Growth Potential Score	7.40
Div. Directional Score	8.53	--

Next Divdend (Est)
(2024-06-03)

£13.88 Estimate 21.51 %

Dividend Stability

0.57 Average

Dividend Score

6.28

Pay Frequency

Quarterly

Yearly Payout

Year	Amount	Yield
1993	£0	0.00%
1994	£0	0.00%
1995	£0	0.00%
1996	£0	0.00%
1997	£0	0.00%
1998	£0	0.00%
1999	£0	0.00%
2000	£0	0.00%
2001	£0	0.00%
2002	£0	0.00%
2003	£0	0.00%
2004	£0	0.00%
2005	£0	0.00%
2006	£0	0.00%
2007	£0	0.00%
2008	£0	0.00%
2009	£0	0.00%
2010	£0	0.00%
2011	£0	0.00%
2012	£0	0.00%
2013	£0	0.00%
2014	£0	0.00%
2015	£0	0.00%
2016	£0	0.00%
2017	£0	0.00%
2018	£100.00	6.78%
2019	£100.00	6.62%
2020	£100.00	5.59%
2021	£100.00	7.21%
2022	£76.25	4.74%
2023	£41.75	2.90%
2024	£0	0.00%

Dividend Commentary

The company's strong Dividend Sustainability Score (DSS) indicates its robust capacity to uphold current dividend levels. Furthermore, its high Dividend Growth Potential Score (DGPS) signals potential dividend growth. In summary, the company provides a promising overall dividend outlook, balancing both sustainability and growth potential.

Top 10 dividend Companies for LSE

Symbol	Title	Last dividend	Frequency	Years Dividend	Yearly Dividend
VMUK.L	Dividend Junior	2023-05-18	Annually	7	1.91%
MWY.L	Dividend Knight	2023-09-28	Semi-Annually	43	0.48%
ELCO.L	Dividend Knight	2023-09-21	Annually	29	0.64%
SIHL.L	Dividend Junior	2023-07-06	Sporadic	11	2.42%
JAGI.L	Dividend King	2023-07-13	Quarterly	27	2.39%
BUR.L	Dividend Knight	2023-11-09	Annually	14	0.70%
PCFT.L	Dividend Knight	2023-08-03	Semi-Annually	11	1.80%
FRES.L	Dividend Knight	2023-08-10	Semi-Annually	17	1.24%
AERI.L	Dividend Knight	2023-08-17	Quarterly	6	2.80%
SUP.L	Dividend Knight	2023-08-31	Annually	4	1.22%

Dividend Sustainability Score (DSS)

Ratio	Actual Value	Weight	Normalized Value	Score	Range
netProfitMarginTTM	0.162	1.500	6.75	10.00	[0 - 0.5]
returnOnAssetsTTM	0.0835	1.200	7.22	8.66	[0 - 0.3]
returnOnEquityTTM	0.387	1.500	6.82	10.00	[0.1 - 1]
payoutRatioTTM	0.456	-1.000	5.44	-5.44	[0 - 1]
currentRatioTTM	0.885	0.800	-0.575	-0.460	[1 - 3]
quickRatioTTM	0.597	0.800	-1.192	-0.954	[0.8 - 2.5]
cashRatioTTM	0.139	1.500	-0.337	-0.505	[0.2 - 2]
debtRatioTTM	0.288	-1.500	5.21	-7.81	[0 - 0.6]
interestCoverageTTM	9.12	1.000	7.73	7.73	[3 - 30]
operatingCashFlowPerShareTTM	1.613	2.00	9.46	10.00	[0 - 30]
freeCashFlowPerShareTTM	1.035	2.00	9.48	10.00	[0 - 20]
debtEquityRatioTTM	1.271	-1.500	4.92	-7.37	[0 - 2.5]
grossProfitMarginTTM	0.720	1.000	1.330	1.330	[0.2 - 0.8]
operatingProfitMarginTTM	0.238	1.000	7.24	7.24	[0.1 - 0.6]
cashFlowToDebtRatioTTM	0.386	1.000	8.97	8.97	[0.2 - 2]
assetTurnoverTTM	0.514	0.800	9.91	7.93	[0.5 - 2]
Total Score				9.66

Dividend Growth Score (DGS)

Ratio	Actual Value	Weight	Normalized Value	Score	Range
peRatioTTM	13.34	1.000	8.75	0	[1 - 100]
returnOnEquityTTM	0.387	2.50	7.95	10.00	[0.1 - 1.5]
freeCashFlowPerShareTTM	1.035	2.00	9.65	10.00	[0 - 30]
dividendYielPercentageTTM	4.44	1.500	10.00	0	[0 - 0.4]
operatingCashFlowPerShareTTM	1.613	2.00	9.46	10.00	[0 - 30]
payoutRatioTTM	0.456	1.500	5.44	-5.44	[0 - 1]
pegRatioTTM	63.01	1.500	10.00	0	[0.5 - 2]
operatingCashFlowSalesRatioTTM	0.216	1.000	7.11	0	[0.1 - 0.5]
Total Score				7.40

GlaxoSmithKline PLC

GSK plc, together with its subsidiaries, engages in the creation, discovery, development, manufacture, and marketing of pharmaceutical products, vaccines, over-the-counter medicines, and health-related consumer products in the United Kingdom, the United States, and internationally. It operates through four segments: Pharmaceuticals, Pharmaceuticals R&D, Vaccines, and Consumer Healthcare. The company offers pharmaceutical products comprising medicines in the therapeutic areas, such as respiratory, HIV, immuno-inflammation, oncology, anti-viral, central nervous system, cardiovascular and urogenital, metabolic, anti-bacterial, and dermatology. It also provides consumer healthcare products in wellness, oral health, nutrition, and skin health categories. The company offers its consumer healthcare products in the form of nasal sprays, tablets, syrups, lozenges, gum and trans-dermal patches, caplets, infant syrup drops, liquid filled suspension, wipes, gels, effervescents, toothpastes, toothbrushes, mouthwashes, denture adhesives and cleansers, topical creams and non-medicated patches, lip balm, gummies, and soft chews. It has collaboration agreements with 23andMe; Lyell Immunopharma, Inc.; Novartis; Sanofi SA; Surface Oncology; Progentec Diagnostics, Inc.; Alector, Inc.; and CureVac AG., as well as strategic partnership with IDEAYA Biosciences, Inc. and Vir Biotechnology, Inc. The company was formerly known as GlaxoSmithKline plc and changed its name to GSK plc in May 2022. GSK plc was founded in 1715 and is headquartered in Brentford, the United Kingdom.